{"denoms":[{"counts":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"255"}],"units":"Participants"}],"groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 IV infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic G-CSF as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"BG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).","id":"BG001","title":"Abiraterone Acetate or Enzalutamide"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.3","value":"69.7"},{"groupId":"BG001","spread":"7.9","value":"69.7"},{"groupId":"BG002","spread":"8.1","value":"69.7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"255"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"255"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"255"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"}],"populationDescription":"Analysis was performed on Intent-to-treat (ITT) population, that included any participant who had been allocated to a randomized treatment regardless of whether the treatment kit was used, analyzed according to the treatment group allocated by randomization."}